1092500-89-4

Basic information

• Product Name: tert-butyl 4-(4-bromo-3-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate
• CAS NO: 1092500-89-4
• Molecular Weight: 344.252
• Mol File: 1092500-89-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-bromo-3-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-bromo-3-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate(1092500-89-4)
• EPA Substance Registry System: tert-butyl 4-(4-bromo-3-methyl-1H-pyrazol-1-yl)piperidine-1-carboxylate(1092500-89-4)

Safety Data

• Hazardous Substances Data: 1092500-89-4(Hazardous Substances Data)

Upstream product

• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 13808-64-5 4-bromo-3-methyl-1H-pyrazole 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 

Downstream Products

• 1092563-68-2 tert-butyl 4-(3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 

Relevant articles and documents

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER

Provided herein are 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X 2 is N and Ring A, Ring B, Ring C, X 1, X su

PYRIDINE AND PYRAZINE DERIVATIVES - 083

The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.